ORY 2001

Drug Profile

ORY 2001

Alternative Names: ORY-2001

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Oryzon
  • Class Nootropics; Small molecules
  • Mechanism of Action Histone demethylase inhibitors; Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Dementia; Huntington's disease; Parkinson's disease
  • Preclinical Multiple sclerosis

Most Recent Events

  • 27 Feb 2017 Pharmacodynamics data from a preclinical study in Multiple sclerosis presented at the 2nd Annual Conference of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-2017)
  • 20 Feb 2017 Oryzon Genomic plans phase II trials in Alzheimer's disease, Multiple sclerosis and other Neurodegenerative diseases
  • 25 Oct 2016 Phase-I clinical trials in Huntington's disease (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top